EP-104GI

N/A

Report date: 2025/09/02 17:34:36

Base Information

Drug NameEP-104GI
Drug Alias NameLong-acting Fluticasone Propionate Injectable Suspension (Eupraxia Pharmaceuticals)EP-104GI
ClassificationSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonistsCytosolic phospholipase A2 agonists
TargetsGlucocorticoid receptorCytosolic phospholipase A2
Therapy Area/IndicationsEosinophilic Esophagitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEupraxia Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesEupraxia Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsEosinophilic Esophagitis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A